Taiwan has built a strong reputation for making innovative medicines broadly accessible, but the next wave of precision therapies, diagnostics, and combination treatments will require new approaches to assessment and reimbursement. As AstraZeneca Taiwan’s Mark Little notes, sustaining this leadership will depend on closer collaboration, faster approvals, and more adaptive funding pathways.
As Gilead expands its oncology focus in Taiwan, the company is working with healthcare stakeholders to improve access to innovative therapies and support patients through increasingly complex treatment journeys.
AI agents may soon initiate transactions on behalf of users, but the final payment step still requires trusted infrastructure. OEN Technology is building systems to power that last mile of AI commerce.
Opening in Taipei this January, Uketamo Hotel rethinks urban hospitality by blending Japanese omotenashi with Taiwanese warmth, framing wellness as a quiet, everyday practice rooted in presence rather than escape.
By combining data from international weather stations and microclimate sensors, the system provides environmental insights that support smarter agricultural decisions.
Founded in 2015, Taiwan Renewable Energy Alliance (TRENA) connects civil society, industry, and policymakers to advance Taiwan’s renewable energy transition. As 2030 targets approach, its work underscores the importance of public consensus and coordinated policy action.
Taiwan is framing trade talks with the United States as a pathway to deeper high-tech partnership, focusing on supply-chain resilience, economic security, and long-term industrial cooperation beyond tariffs.
Marking 25 years in Taiwan, Corning reflects on its evolution from a greenfield manufacturing site to an integrated hub for R&D, engineering, and global innovation. Built on long-term partnerships, local talent, and cross-sector collaboration, Taiwan remains central to Corning’s next chapter in AI, advanced materials, and semiconductors.
Taiwan’s fight against antimicrobial resistance is entering a new phase as Taiwan CDC and Pfizer formalize a public-private partnership to strengthen surveillance, research, and public education. The new MOU underscores the urgency of AMR and aligns with Taiwan’s expanding One Health strategy.
As BMS celebrates six decades in Taiwan, the company is deepening its commitment to bringing innovative therapies to patients faster through strong local talent, clinical excellence, and policy collaboration.
